{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T11:46:25Z","timestamp":1794311185295,"version":"4.9.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The immune-specialized environment of the healthy brain is tightly regulated to prevent excessive neuroinflammation. However, after cancer development, a tissue-specific conflict between brain-preserving immune suppression and tumor-directed immune activation may ensue. To interrogate potential roles of T cells in this process, we profiled these cells from individuals with primary or metastatic brain cancers via integrated analyses on the single-cell and bulk population levels. Our analysis revealed similarities and differences in T cell biology between individuals, with the most pronounced differences observed in a subgroup of individuals with brain metastasis, characterized by accumulation of\n                    <jats:italic>CXCL13<\/jats:italic>\n                    -expressing CD39\n                    <jats:sup>+<\/jats:sup>\n                    potentially tumor-reactive T (pTRT) cells. In this subgroup, high pTRT cell abundance was comparable to that in primary lung cancer, whereas all other brain tumors had low levels, similar to primary breast cancer. These findings indicate that T cell-mediated tumor reactivity can occur in certain brain metastases and may inform stratification for treatment with immunotherapy.\n                  <\/jats:p>","DOI":"10.1038\/s43018-023-00566-3","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T12:01:35Z","timestamp":1684756895000},"page":"908-924","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Phenotypic diversity of T cells in human primary and metastatic brain tumors revealed by multiomic interrogation"],"prefix":"10.1038","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9059-1304","authenticated-orcid":false,"given":"Vladimir","family":"Wischnewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roeltje R.","family":"Maas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola Guerrero","family":"Aruffo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2764-4845","authenticated-orcid":false,"given":"Klara","family":"Soukup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6613-2354","authenticated-orcid":false,"given":"Giovanni","family":"Galletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Kornete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Galland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-7929","authenticated-orcid":false,"given":"Nadine","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Lilja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0327-4686","authenticated-orcid":false,"given":"Pratyaksha","family":"Wirapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao","family":"Lourenco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy T.","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas F.","family":"Hottinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Brouland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnese","family":"Losurdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Voulaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Alloisio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0855-6495","authenticated-orcid":false,"given":"Monika E.","family":"Hegi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1964-7678","authenticated-orcid":false,"given":"Enrico","family":"Lugli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6332-2598","authenticated-orcid":false,"given":"Johanna A.","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,22]]},"reference":[{"key":"566_CR1","doi-asserted-by":"crossref","unstructured":"Azzarelli, R., Simons, B. D. & Philpott, A. The developmental origin of brain tumours: a cellular and molecular framework. Development 145, dev162693 (2018).","DOI":"10.1242\/dev.162693"},{"key":"566_CR2","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ejca.2021.12.005","volume":"162","author":"A Steindl","year":"2022","unstructured":"Steindl, A. et al. Changing characteristics, treatment approaches and survival of patients with brain metastasis: data from 6,031 individuals over an observation period of 30 years. Eur. J. Cancer 162, 170\u2013181 (2022).","journal-title":"Eur. J. Cancer"},{"key":"566_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-68011-4","volume":"10","author":"MTC Poon","year":"2020","unstructured":"Poon, M. T. C., Sudlow, C. L. M., Figueroa, J. D. & Brennan, P. M. Longer-term (\u22652 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis. Sci. Rep. 10, 11622 (2020).","journal-title":"Sci. Rep."},{"key":"566_CR4","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1200\/JCO.20.01255","volume":"38","author":"PW Sperduto","year":"2020","unstructured":"Sperduto, P. W. et al. Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient. J. Clin. Oncol. 38, 3773\u20133784 (2020).","journal-title":"J. Clin. Oncol."},{"key":"566_CR5","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.cell.2020.05.007","volume":"181","author":"F Klemm","year":"2020","unstructured":"Klemm, F. et al. Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells. Cell 181, 1643\u20131660 (2020).","journal-title":"Cell"},{"key":"566_CR6","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ccell.2017.02.009","volume":"31","author":"DF Quail","year":"2017","unstructured":"Quail, D. F. & Joyce, J. A. The microenvironmental landscape of brain tumors. Cancer Cell 31, 326\u2013341 (2017).","journal-title":"Cancer Cell"},{"key":"566_CR7","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.cell.2020.04.055","volume":"181","author":"E Friebel","year":"2020","unstructured":"Friebel, E. et al. Single-cell mapping of human brain cancer reveals tumor-specific instruction of tissue-invading leukocytes. Cell 181, 1626\u20131642 (2020).","journal-title":"Cell"},{"key":"566_CR8","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/S1470-2045(21)00545-3","volume":"22","author":"HA Tawbi","year":"2021","unstructured":"Tawbi, H. A. et al. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncol. 22, 1692\u20131704 (2021).","journal-title":"Lancet Oncol."},{"key":"566_CR9","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","volume":"21","author":"SB Goldberg","year":"2020","unstructured":"Goldberg, S. B. et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol. 21, 655\u2013663 (2020).","journal-title":"Lancet Oncol."},{"key":"566_CR10","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s11060-020-03481-0","volume":"151","author":"HY Chan","year":"2021","unstructured":"Chan, H. Y., Choi, J., Jackson, C. & Lim, M. Combination immunotherapy strategies for glioblastoma. J. Neurooncol. 151, 375\u2013391 (2021).","journal-title":"J. Neurooncol."},{"key":"566_CR11","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509\u20132520 (2015).","journal-title":"N. Engl. J. Med."},{"key":"566_CR12","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle, A. et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21, 1353\u20131365 (2020).","journal-title":"Lancet Oncol."},{"key":"566_CR13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/jnci\/djx123","volume":"110","author":"B Mlecnik","year":"2018","unstructured":"Mlecnik, B. et al. Comprehensive intrametastatic immune quantification and major impact of immunoscore on survival. J. Natl Cancer Inst. 110, 97\u2013108 (2018).","journal-title":"J. Natl Cancer Inst."},{"key":"566_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-018-1080-0","volume":"35","author":"A Uryvaev","year":"2018","unstructured":"Uryvaev, A., Passhak, M., Hershkovits, D., Sabo, E. & Bar-Sela, G. The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma. Med. Oncol. 35, 25 (2018).","journal-title":"Med. Oncol."},{"key":"566_CR15","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1158\/1078-0432.CCR-19-2184","volume":"26","author":"K Pocha","year":"2020","unstructured":"Pocha, K. et al. Surfactant expression defines an inflamed subtype of lung adenocarcinoma brain metastases that correlates with prolonged survival. Clin. Cancer Res. 26, 2231\u20132243 (2020).","journal-title":"Clin. Cancer Res."},{"key":"566_CR16","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41568-019-0235-4","volume":"20","author":"AM van der Leun","year":"2020","unstructured":"van der Leun, A. M., Thommen, D. S. & Schumacher, T. N. CD8+ T cell states in human cancer: insights from single-cell analysis. Nat. Rev. Cancer 20, 218\u2013232 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"566_CR17","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41586-020-2056-8","volume":"579","author":"TD Wu","year":"2020","unstructured":"Wu, T. D. et al. Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature 579, 274\u2013278 (2020).","journal-title":"Nature"},{"key":"566_CR18","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","volume":"25","author":"KE Yost","year":"2019","unstructured":"Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 25, 1251\u20131259 (2019).","journal-title":"Nat. Med."},{"key":"566_CR19","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s43018-021-00292-8","volume":"3","author":"B Liu","year":"2022","unstructured":"Liu, B. et al. Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer. Nat. Cancer 3, 108\u2013121 (2022).","journal-title":"Nat. Cancer"},{"key":"566_CR20","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller, B. C. et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat. Immunol. 20, 326\u2013336 (2019).","journal-title":"Nat. Immunol."},{"key":"566_CR21","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","volume":"175","author":"M Sade-Feldman","year":"2018","unstructured":"Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998\u20131013 (2018).","journal-title":"Cell"},{"key":"566_CR22","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/j.ccell.2021.10.009","volume":"39","author":"AM Leader","year":"2021","unstructured":"Leader, A. M. et al. Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification. Cancer Cell 39, 1594\u20131609 (2021).","journal-title":"Cancer Cell"},{"key":"566_CR23","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","volume":"184","author":"K Litchfield","year":"2021","unstructured":"Litchfield, K. et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 184, 596\u2013614 (2021).","journal-title":"Cell"},{"key":"566_CR24","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.ccell.2021.09.010","volume":"39","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell 39, 1578\u20131593 (2021).","journal-title":"Cancer Cell"},{"key":"566_CR25","doi-asserted-by":"crossref","unstructured":"Lowery, F. J. et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science 375, 877\u2013884 (2022).","DOI":"10.1126\/science.abl5447"},{"key":"566_CR26","doi-asserted-by":"publisher","first-page":"abe6474","DOI":"10.1126\/science.abe6474","volume":"374","author":"L Zheng","year":"2021","unstructured":"Zheng, L. et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science 374, abe6474 (2021).","journal-title":"Science"},{"key":"566_CR27","doi-asserted-by":"publisher","first-page":"4692","DOI":"10.1038\/s41596-021-00594-2","volume":"16","author":"RR Maas","year":"2021","unstructured":"Maas, R. R. et al. An integrated pipeline for comprehensive analysis of immune cells in human brain tumor clinical samples. Nat. Protoc. 16, 4692\u20134721 (2021).","journal-title":"Nat. Protoc."},{"key":"566_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1171-9","volume":"18","author":"A Guillaumet-Adkins","year":"2017","unstructured":"Guillaumet-Adkins, A. et al. Single-cell transcriptome conservation in cryopreserved cells and tissues. Genome Biol. 18, 45 (2017).","journal-title":"Genome Biol."},{"key":"566_CR29","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1038\/s41590-020-0791-5","volume":"21","author":"G Galletti","year":"2020","unstructured":"Galletti, G. et al. Two subsets of stem-like CD8+ memory T cell progenitors with distinct fate commitments in humans. Nat. Immunol. 21, 1552\u20131562 (2020).","journal-title":"Nat. Immunol."},{"key":"566_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23324-4","volume":"12","author":"M Andreatta","year":"2021","unstructured":"Andreatta, M. et al. Interpretation of T cell states from single-cell transcriptomics data using reference atlases. Nat. Commun. 12, 2965 (2021).","journal-title":"Nat. Commun."},{"key":"566_CR31","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41586-021-03752-4","volume":"596","author":"JX Caushi","year":"2021","unstructured":"Caushi, J. X. et al. Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature 596, 126\u2013132 (2021).","journal-title":"Nature"},{"key":"566_CR32","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.ccell.2022.03.012","volume":"40","author":"KI Hanada","year":"2022","unstructured":"Hanada, K. I. et al. A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers. Cancer Cell 40, 479\u2013493 (2022).","journal-title":"Cancer Cell"},{"key":"566_CR33","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-021-03704-y","volume":"596","author":"G Oliveira","year":"2021","unstructured":"Oliveira, G. et al. Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. Nature 596, 119\u2013125 (2021).","journal-title":"Nature"},{"key":"566_CR34","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41586-018-0130-2","volume":"557","author":"Y Simoni","year":"2018","unstructured":"Simoni, Y. et al. Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature 557, 575\u2013579 (2018).","journal-title":"Nature"},{"key":"566_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05072-0","volume":"9","author":"T Duhen","year":"2018","unstructured":"Duhen, T. et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat. Commun. 9, 2724 (2018).","journal-title":"Nat. Commun."},{"key":"566_CR36","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1038\/s42003-021-02595-z","volume":"4","author":"A Losurdo","year":"2021","unstructured":"Losurdo, A. et al. Single-cell profiling defines the prognostic benefit of CD39high tissue resident memory CD8+ T cells in luminal-like breast cancer. Commun. Biol. 4, 1117 (2021).","journal-title":"Commun. Biol."},{"key":"566_CR37","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.ccell.2021.10.008","volume":"39","author":"J Duraiswamy","year":"2021","unstructured":"Duraiswamy, J. et al. Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. Cancer Cell 39, 1623\u20131642 (2021).","journal-title":"Cancer Cell"},{"key":"566_CR38","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41586-019-1836-5","volume":"576","author":"CS Jansen","year":"2019","unstructured":"Jansen, C. S. et al. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature 576, 465\u2013470 (2019).","journal-title":"Nature"},{"key":"566_CR39","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1084\/jem.20180684","volume":"215","author":"J Brummelman","year":"2018","unstructured":"Brummelman, J. et al. High-dimensional single cell analysis identifies stem-like cytotoxic CD8+ T cells infiltrating human tumors. J. Exp. Med. 215, 2520\u20132535 (2018).","journal-title":"J. Exp. Med."},{"key":"566_CR40","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon, J. & Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov. 18, 197\u2013218 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"566_CR41","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce, J. A. & Fearon, D. T. T cell exclusion, immune privilege, and the tumor microenvironment. Science 348, 74\u201380 (2015).","journal-title":"Science"},{"key":"566_CR42","doi-asserted-by":"publisher","first-page":"4296","DOI":"10.1158\/1078-0432.CCR-10-2557","volume":"17","author":"J Lohr","year":"2011","unstructured":"Lohr, J. et al. Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-\u03b2. Clin. Cancer Res. 17, 4296\u20134308 (2011).","journal-title":"Clin. Cancer Res."},{"key":"566_CR43","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"566_CR44","doi-asserted-by":"crossref","unstructured":"Wang, Z. et al. Carcinomas assemble a filamentous CXCL12\u2013keratin-19 coating that suppresses T cell-mediated immune attack. Proc. Natl Acad. Sci. USA 119, e2119463119 (2022).","DOI":"10.1073\/pnas.2119463119"},{"key":"566_CR45","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41571-021-00562-5","volume":"18","author":"M Lopez de Rodas","year":"2021","unstructured":"Lopez de Rodas, M. & Schalper, K. A. Tumour antigen-induced T cell exhaustion\u2014the archenemy of immune-hot malignancies. Nat. Rev. Clin. Oncol. 18, 749\u2013750 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"566_CR46","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415\u2013421 (2013).","journal-title":"Nature"},{"key":"566_CR47","doi-asserted-by":"publisher","first-page":"100620","DOI":"10.1016\/j.xcrm.2022.100620","volume":"3","author":"LJ Sudmeier","year":"2022","unstructured":"Sudmeier, L. J. et al. Distinct phenotypic states and spatial distribution of CD8+ T cell clonotypes in human brain metastases. Cell Rep. Med. 3, 100620 (2022).","journal-title":"Cell Rep. Med."},{"key":"566_CR48","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1172\/JCI130426","volume":"130","author":"G Alvisi","year":"2020","unstructured":"Alvisi, G. et al. IRF4 instructs effector Treg differentiation and immune suppression in human cancer. J. Clin. Invest. 130, 3137\u20133150 (2020).","journal-title":"J. Clin. Invest."},{"key":"566_CR49","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.cell.2020.09.064","volume":"183","author":"IH Guldner","year":"2020","unstructured":"Guldner, I. H. et al. CNS-native myeloid cells drive immune suppression in the brain metastatic niche through CXCL10. Cell 183, 1234\u20131248 (2020).","journal-title":"Cell"},{"key":"566_CR50","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/nm934","volume":"9","author":"C Uyttenhove","year":"2003","unstructured":"Uyttenhove, C. et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9, 1269\u20131274 (2003).","journal-title":"Nat. Med."},{"key":"566_CR51","doi-asserted-by":"crossref","unstructured":"Gonzalez, H. et al. Cellular architecture of human brain metastases. Cell 185, 729\u2013745 (2022).","DOI":"10.1016\/j.cell.2021.12.043"},{"key":"566_CR52","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/s43018-022-00433-7","volume":"3","author":"B Liu","year":"2022","unstructured":"Liu, B., Zhang, Y., Wang, D., Hu, X. & Zhang, Z. Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade. Nat. Cancer 3, 1123\u20131136 (2022).","journal-title":"Nat. Cancer"},{"key":"566_CR53","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41587-021-01070-8","volume":"40","author":"D Chowell","year":"2022","unstructured":"Chowell, D. et al. Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. Nat. Biotechnol. 40, 499\u2013506 (2022).","journal-title":"Nat. Biotechnol."},{"key":"566_CR54","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1038\/s41596-019-0166-2","volume":"14","author":"J Brummelman","year":"2019","unstructured":"Brummelman, J. et al. Development, application and computational analysis of high-dimensional fluorescent antibody panels for single-cell flow cytometry. Nat. Protoc. 14, 1946\u20131969 (2019).","journal-title":"Nat. Protoc."},{"key":"566_CR55","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"566_CR56","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/1471-2105-12-323","volume":"12","author":"B Li","year":"2011","unstructured":"Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome. BMC Bioinformatics 12, 323 (2011).","journal-title":"BMC Bioinformatics"},{"key":"566_CR57","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"566_CR58","first-page":"1438","volume":"5","author":"Y Chen","year":"2016","unstructured":"Chen, Y., Lun, A. T. & Smyth, G. K. From reads to genes to pathways: differential expression analysis of RNA-seq experiments using Rsubread and the edgeR quasi-likelihood pipeline. F1000Res 5, 1438 (2016).","journal-title":"F1000Res"},{"key":"566_CR59","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"566_CR60","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nmeth.3364","volume":"12","author":"DA Bolotin","year":"2015","unstructured":"Bolotin, D. A. et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat. Methods 12, 380\u2013381 (2015).","journal-title":"Nat. Methods"},{"key":"566_CR61","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114\u20132120 (2014).","journal-title":"Bioinformatics"},{"key":"566_CR62","doi-asserted-by":"publisher","first-page":"e1004503","DOI":"10.1371\/journal.pcbi.1004503","volume":"11","author":"M Shugay","year":"2015","unstructured":"Shugay, M. et al. VDJtools: unifying post-analysis of T cell receptor repertoires. PLoS Comput. Biol. 11, e1004503 (2015).","journal-title":"PLoS Comput. Biol."},{"key":"566_CR63","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587 (2021).","journal-title":"Cell"},{"key":"566_CR64","doi-asserted-by":"crossref","unstructured":"Bunis, D. G., Andrews, J., Fragiadakis, G. K., Burt, T. D. & Sirota, M. dittoSeq: universal user-friendly single-cell and bulk RNA sequencing visualization toolkit. Bioinformatics 36, 5535\u20135536 (2020).","DOI":"10.1093\/bioinformatics\/btaa1011"},{"key":"566_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-019-1874-1","volume":"20","author":"C Hafemeister","year":"2019","unstructured":"Hafemeister, C. & Satija, R. Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. Genome Biol. 20, 296 (2019).","journal-title":"Genome Biol."},{"key":"566_CR66","doi-asserted-by":"publisher","first-page":"47","DOI":"10.12688\/f1000research.22139.1","volume":"9","author":"N Borcherding","year":"2020","unstructured":"Borcherding, N., Bormann, N. L. & Kraus, G. scRepertoire: an R-based toolkit for single-cell immune receptor analysis. F1000Res 9, 47 (2020).","journal-title":"F1000Res"},{"key":"566_CR67","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/cyto.a.22625","volume":"87","author":"S Van Gassen","year":"2015","unstructured":"Van Gassen, S. et al. FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data. Cytometry A 87, 636\u2013645 (2015).","journal-title":"Cytometry A"},{"key":"566_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).","journal-title":"Sci. Rep."},{"key":"566_CR69","doi-asserted-by":"publisher","unstructured":"Schmidt, U., Weigert, M., Broaddus, C. & Myers, G. Cell detection with star\u2013convex polygons. Preprint at https:\/\/doi.org\/10.48550\/arXiv.1806.03535 (2018).","DOI":"10.48550\/arXiv.1806.03535"}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-023-00566-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-023-00566-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-023-00566-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T19:03:37Z","timestamp":1687806217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-023-00566-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,22]]},"references-count":69,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["566"],"URL":"https:\/\/doi.org\/10.1038\/s43018-023-00566-3","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,22]]},"assertion":[{"value":"30 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.E.H. has an advisory role at TME Pharma. E.L. receives research grants from Bristol Meyers Squibb on a topic unrelated to this manuscript. J.A.J. currently serves on the scientific advisory board of Pionyr Immunotherapeutics and received an honorarium for speaking at a research symposium organized by Bristol Meyers Squibb (last 3 years). All other authors have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}